Fig. 1From: Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myelomaMeta-analysis of the response rate of carfilzomib (a), panobinostat (b), and elotuzumab (c) combination regimens in patients with relapsed and refractory multiple myeloma. n number of the enrolled patients, CI 95 % confidence interval, Random random effects modelBack to article page